A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34

Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

Chapman PB, D’Angelo SP, Wolchok JD (2015) Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 372:2073–2074

Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved suvival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

Okada Y, Wu D, Trynka G et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376–381

Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123

Li G, Shi F, Liu J, Li Y (2014) The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis. Diagn pathol 9:157